Last 36 quarters of trend data · Healthcare · Biotechnology
Quarterly valuation ratios — annualised for comparability. YoY Δ shows same-quarter-prior-year change.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio → | -0.68 | — | — | — | — | — | — | — | — | — | — | 2.10 | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| P/S Ratio | 1.45 | 13.98 | 5.61 | 2.13 | 1.90 | 0.24 | 0.78 | 2.56 | 8.33 | 2.31 | 6.67 | 0.58 | 3.11 | 6.74 | 5.35 | 13.29 | 2.89 | 2.18 | 16.20 | 16.12 | 25.60 |
| — | +5802.4% | +621.6% | -16.8% | -77.2% | -89.8% | -88.4% | +345.5% | +168.2% | -65.6% | +24.7% | -95.7% | +7.5% | +209.5% | -67.0% | -17.6% | -88.7% | -71.5% | -9.1% | -33.4% | +379.4% | |
| P/B Ratio | — | — | — | — | — | — | — | 3.40 | 2.55 | 1.56 | 3.54 | 1.75 | 1.87 | 1.81 | 1.46 | 2.11 | 1.26 | 1.17 | 1.73 | 2.72 | 3.08 |
| — | — | — | — | — | — | — | +94.7% | +36.4% | -13.8% | +142.1% | -17.3% | +48.0% | +55.0% | -15.6% | -22.3% | -58.9% | -58.0% | -49.0% | +12.8% | +97.2% | |
| P/FCF | — | — | — | — | — | — | — | — | — | 6.84 | — | 5.18 | — | — | — | — | 1.12 | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — | — | 1.26 | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — | — | 1.02 | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Quarterly margins and returns. Watch for margin compression across consecutive quarters.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 92.9% | 100.0% | 91.2% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 93.0% | 86.5% | 100.0% | 100.0% | -299.5% | 100.0% | -399.7% | 100.0% | 100.0% | -408.6% | -180.9% | -212.3% |
| — | 0.0% | -8.8% | 0.0% | 0.0% | +7.5% | +15.7% | 0.0% | 0.0% | +131.1% | -13.5% | +125.0% | 0.0% | -399.5% | +124.5% | -121.0% | +147.1% | +923.7% | -658.0% | -3.6% | -2360.7% | |
| Operating Margin | -102.4% | -303.8% | -203.9% | -289.0% | -499.9% | -5.2% | -393.8% | -440.7% | -797.2% | -189.4% | -435.0% | 37.9% | -260.1% | -443.5% | -333.3% | -570.2% | -84.3% | -69.0% | -663.6% | -328.9% | -407.1% |
| — | -5688.9% | +48.2% | +34.4% | +37.3% | +97.2% | +9.5% | -1261.3% | -206.5% | +57.3% | -30.5% | +106.7% | -208.3% | -543.0% | +49.8% | -73.4% | +79.3% | -97.3% | -411.8% | -9.6% | -583.4% | |
| Net Margin | -186.5% | -391.6% | -265.0% | -401.5% | -586.6% | -18.0% | -436.6% | -489.2% | -572.6% | -186.8% | -447.5% | 27.3% | -291.2% | -370.0% | -394.9% | -400.8% | -77.5% | -92.6% | -663.2% | -357.8% | -362.8% |
| — | -2071.0% | +39.3% | +17.9% | -2.4% | +90.3% | +2.4% | -1890.8% | -96.6% | +49.5% | -13.3% | +106.8% | -275.8% | -299.6% | +40.5% | -12.0% | +78.6% | -322.1% | -220.3% | +50.3% | -477.3% |
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | — | — | — | — | — | — | -808.6% | -93.0% | -37.0% | -38.4% | -47.0% | 23.7% | -36.9% | -22.7% | -24.9% | -15.5% | -8.9% | -12.1% | -16.5% | -14.2% | -10.5% |
| — | — | — | — | — | — | -1620.1% | -492.1% | -0.4% | -69.4% | -89.0% | +253.1% | -315.5% | -87.0% | -50.4% | -8.9% | +15.0% | -505.4% | -74.2% | +31.2% | -237.5% | |
| ROA | -68.1% | -17.7% | -18.5% | -24.4% | -24.1% | -3.9% | -21.4% | -17.3% | -10.4% | -10.8% | -13.3% | 6.9% | -11.0% | -9.4% | -13.1% | -8.6% | -5.0% | -7.5% | -12.1% | -10.7% | -8.5% |
| — | -348.2% | +13.7% | -41.2% | -132.3% | +63.4% | -61.0% | -350.8% | +5.7% | -14.9% | -1.8% | +180.4% | -121.8% | -24.1% | -7.9% | +19.9% | +41.4% | -340.6% | -50.3% | +37.0% | -244.2% | |
| ROIC | — | — | — | -56.6% | — | -38.9% | — | — | -206.2% | -49.1% | -48.5% | 35.4% | -178.9% | -50.3% | -16.1% | -18.0% | -8.6% | -6.7% | -11.1% | -8.9% | -8.9% |
| — | — | — | — | — | +20.7% | — | — | -15.2% | +2.4% | -202.1% | +297.1% | -1988.2% | -652.4% | -44.8% | -102.1% | +3.3% | -150.9% | -66.0% | +15.4% | -105.7% |
Quarterly solvency trend — watch for debt spikes or covenant pressure.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | — | — | — | — | — | — | — | 0.52 | 0.22 | 0.17 | 0.29 | 0.22 | 0.34 | 0.31 | 0.25 | 0.25 | 0.23 | 0.27 | 0.26 | 0.23 | 0.21 |
| — | — | — | — | — | — | — | +131.0% | -34.2% | -44.5% | +14.0% | -11.3% | +47.4% | +18.4% | -4.5% | +11.6% | +11.8% | +228.7% | +227.6% | +207.3% | +106.2% | |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — | 0.75 | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Current Ratio | 2.01 | 3.32 | 3.12 | 2.01 | 2.53 | 3.12 | 2.16 | 2.60 | 3.09 | 3.41 | 4.46 | 4.50 | 5.18 | 6.14 | 5.11 | 5.31 | 5.95 | 7.44 | 5.90 | 5.24 | 7.07 |
| — | +6.4% | +44.5% | -22.8% | -18.0% | -8.6% | -51.6% | -42.1% | -40.3% | -44.4% | -12.8% | -15.3% | -12.9% | -17.5% | -13.4% | +1.4% | -15.9% | -30.0% | -49.7% | -59.0% | -27.6% | |
| Quick Ratio | 2.01 | 3.32 | 3.12 | 2.01 | 2.53 | 3.12 | 2.16 | 2.60 | 3.09 | 3.41 | 4.46 | 4.50 | 5.18 | 6.14 | 5.11 | 5.31 | 5.95 | 7.44 | 5.90 | 5.24 | 7.07 |
| — | +6.4% | +44.5% | -22.8% | -18.0% | -8.6% | -51.6% | -42.1% | -40.3% | -44.4% | -12.8% | -15.3% | -12.9% | -17.5% | -13.4% | +1.4% | -15.9% | -30.0% | -49.7% | -59.0% | -27.6% | |
| Interest Coverage | -4.00 | -2.91 | -3.07 | -3.54 | -4.46 | -0.09 | -4.46 | -7.07 | -5.17 | -4.50 | -5.43 | 6.37 | -4.47 | -13.76 | -15.63 | — | -5.99 | -38.58 | -59.56 | -57.25 | -42.29 |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Includes 30+ ratios · 36 years · Updated daily
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying STRO stock.
Sutro Biopharma, Inc.'s current P/E is -0.7x. Quarterly P/E ratios can vary due to seasonal revenue patterns and one-time charges.
Sutro Biopharma, Inc.'s current operating margin is -102.4%. Margins have been expanding over recent quarters. Quarterly margins are particularly useful for identifying trend inflections that annual data smooths over.
Quarterly financial ratios reveal short-term trend shifts — margin compression, debt spikes, or valuation re-ratings — that annual figures smooth over. They're essential for active investors tracking Sutro Biopharma, Inc.'s business trajectory between earnings reports.